Muzumdar Lab
@MuzumdarLab
Studying genetic, environmental, and host factors in tumor progression of #PancreaticCancer and #LungCancer @YaleGenetics @YaleCancer @CancerYale @YaleMed
🎉 So proud of my wife @nanamedici on her latest co–first author paper in @ScienceTransMed! 🚀 Her team introduces TMAB3 — a tumor-targeted, RNA-binding antibody that delivers RNA directly into tumors after systemic injection. 📖 science.org/doi/10.1126/sc…
Stellar flash talk and poster presentation on #ubiquitination regulators in #KRAS inhibitor resistance by our own #CassieMarkham @FASEBorg Protein Phosphorylation! @YaleGenetics @YaleCancer @CancerYale
Way to go, @Xiangyu_GigiG, for a fantastic talk on how #PI3K governs resistance to #KRAS inhibition in #PancreaticCancer cells @FASEBorg Protein Phosphorylation! @yalepathology @YaleCancer @CancerYale @moitrayee_lab @JuraLab_UCSF. Check out her preprint: biorxiv.org/content/10.110…
📢📢 Announcing the Human Genome Sciences track - a brand new addition to the Yale graduate program that aims to train the next generation of scientists in the areas of human genomics, genetics, and bioinformatics. medicine.yale.edu/bbs/tracks/hum…
A rare #kidneycancer, chromophobe RCC, resists traditional immunotherapy because of its ability to hide from the immune system. A @YaleCancer-led study in @JCO_ASCO reveals the tumor’s unique biology and urgent need for new treatment strategies. yalecancercenter.org/news-article/n……
Congrats to our very own @ChristianFRuiz and #DanMcQuaid for winning awards for their presentations at @YaleCancer trainee colloquium! @YaleGenetics @CancerYale
We recently hosted the 8th Annual #CRTEC Trainee Colloquium at @YaleCancer with trainee presentations for 90+ faculty & @UNewHaven students. Congrats to our 5 Research Excellence awardees: Christian Ruiz, PhD (@MuzumdarLab), Ana Greenberg, Daniel McQuaid, @ElizLGodfreyMD, &…
If PI3K can activate wild-type RAS, then KRAS inhibition alone might not be enough in #PDAC. Huge implications for understanding KRASi resistance 👏
1/🚨 New preprint out!🚨 We uncovered that #PI3K-driven wild-type RAS activation bypasses #KRAS inhibition in pancreatic adenocarcinoma (#PDAC) to drive #resistance. 🔑PI3K isn’t just a downstream RAS effector – it can be an upstream RAS regulator. 📄 biorxiv.org/content/10.110…